- Policy
- What is the difference between Remdesivir & VSF
- by Lee, Tak-Sun Mar 9, 2020 07:59am
- There are two investigational drugs approved by the MFDS for COVID-19 patients as of the 5th. The first is the antiviral drug 'Remdesivir' of the US global pharmaceutical company Gilead Science, and the other is the antiviral candidate called 'VSF' of Korean bioventure Immunemd. However, the reasons for authorizing the administration of
- Policy
- Off-label Mabthera use on NMO patient rejected
- by Lee, Hye-Kyung Mar 9, 2020 07:59am
- Non-reimbursed use of Mabthera injection (rituximab) on a female patient with neuromyelitis optica (NMO), who is planning on a pregnancy, has been denied. Korea’s Health Insurance Review and Assessment Service (HIRA) preliminarily reviews off-label non-reimbursed use of drugs to prevent using drugs lacking medical evidence or having saf
- Company
- Fear of unstable Indian API supply spreads with COVID-19
- by Chon, Seung-Hyun Mar 9, 2020 07:59am
- Due to the outbreak of 2019 novel coronavirus (COVID-19), Indian government started limiting the export of active pharmaceutical ingredient. Pharmaceutical companies’ concern of supply shortage is now imminent as COVID-19 could impede pharmaceutical ingredient export from China and India in a long-term. According to industry sources on Mar.
- Save Daegu! Professors jumped into the COVID-19 front
- by moon, sung ho Mar 8, 2020 10:06pm
- The Life Care Center for the mild COVID-19 confirmed patients in Daegu and Gyeongbuk area is opening one after another, and the dispatch of large hospital medical staff to manage it continues. In effect, they are acting as controller for the management of patients who enter the care center. According to the medical community on the 6th, me
- Company
- MOHW: “Cancer Committee to be rescheduled in March”
- by Eo, Yun-Ho Mar 6, 2020 06:06am
- The Cancer Deliberation Committee meeting initially canceled due to COVID-19 outbreak would be rescheduled again soon. Pharmaceutical industry sources reported Korea’s Ministry of Health and Welfare (MOHW) plans to review some of drugs on paper, but to conduct vis-à-vis review on significant drugs applying for reimbursement expan
- Policy
- ₩11 trillion is organized in supplementary budget
- by Lee, Jeong-Hwan Mar 6, 2020 06:06am
- The government will finalize the revised supplementary budget for COVID-19 at &8361;11.7 trillion and submit it to the National Assembly. The budget details include reinforcing infectious disease prevention system, restoration of damages to small business owners, support for public welfare and employment, and support for stagnant local e
- Company
- MFDS clears varicella vaccine license for GC Pharma
- by Lee, Seok-Jun Mar 6, 2020 06:06am
- GC Pharma announced on Mar. 4 its chickenpox vaccine ‘Varycella’ injection has recently won an item license from Ministry of Food and Drug Safety for the Korean market. Like other existing chickenpox vaccines, the company stated Varycella is a live attenuated varicella virus vaccine. The Korean company was able to push up the prod
- Company
- Industry fears sales ban as NDMA risk in metformin rekindled
- by Chon, Seung-Hyun Mar 6, 2020 06:06am
- The risk of impurity found in metformin could resurface due to another warning from the U.S.-based private research firm. The pharmaceutical industry’s concern deepens as the same research firm that warned about ranitidine risk last year published the metformin analytic data. Already pharmaceutical companies fear global health authoritie
- Opinion
- [Reporter’s view] Did they act honorably?
- by Kim, Jin-Gu Mar 6, 2020 06:05am
- Companies willing to develop COVID-19 treatment (or vaccines). Recently, press releases of this kind have increased in the reporter's mailbox. With the spread of the COVID-19 crisis, many pharmaceutical companies are jumping into the development of drugs or vaccines. But some do not seem pure intentions. It is obviously expected to float
- Are we short on treatments for over 5000 COVID-19 patients?
- by 박상준 Mar 5, 2020 06:34am
- As of 4 p.m. on Mar. 4, the number of confirmed COVID-19 cases in Korea has reached 5,328. The public is now closely watching the supply capacity of insurance-covered treatments. Apparently, the half of the reimbursed treatment list is imported from overseas. Fortunately, the healthcare sources report the pharmaceutical supply shortage i
